Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Codex DNA, Inc. DNAY
$1.30
-$0.35 (-26.55%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
38324231.00000000
-
week52high
11.02
-
week52low
1.08
-
Revenue
27435000
-
P/E TTM
-1
-
Beta
0.00000000
-
EPS
0.00000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 ноя 2022 г. в 21:30
Описание компании
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Keybanc | Overweight | Overweight | 28 мар 2022 г. |
| Keybanc | Overweight | 13 июл 2021 г. | |
| Jefferies | Buy | 13 июл 2021 г. | |
| Cowen & Co. | Outperform | 13 июл 2021 г. | |
| Keybanc | Overweight | Overweight | 09 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Nelson Todd Robert | A | 122516 | 122516 | 11 ноя 2022 г. |
| Hunter Brent M. | A | 125000 | 125000 | 04 авг 2022 г. |
| Esser Eric Eugene | A | 50000 | 50000 | 04 авг 2022 г. |
| Gibson Daniel Glenn | A | 100000 | 100000 | 04 авг 2022 г. |
| TUMOLO ANNETTE | A | 111917 | 111917 | 20 июл 2022 г. |
| TUMOLO ANNETTE | A | 74611 | 74611 | 20 июл 2022 г. |
| Hunter Brent M. | A | 51300 | 51300 | 08 июл 2022 г. |
| Esser Eric Eugene | A | 225000 | 225000 | 15 июн 2022 г. |
| Jackson Andrea Liapis | A | 30945 | 30945 | 09 июн 2022 г. |
| Jackson Andrea Liapis | A | 20630 | 20630 | 09 июн 2022 г. |
Новостная лента
Telesis Bio, Inc. (DNAY) Q3 2022 Earnings Call Transcript
Seeking Alpha
12 ноя 2022 г. в 20:53
Telesis Bio, Inc. (NASDAQ:DNAY ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Todd Nelson - CEO Brent Hunter - VP, Finance Conference Call Participants Brandon Couillard - Jefferies Operator Welcome to the Q3 2022 Telesis Bio Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
Codex DNA (DNAY) Reports Q3 Loss, Tops Revenue Estimates
Zacks Investment Research
08 ноя 2022 г. в 21:04
Codex DNA (DNAY) delivered earnings and revenue surprises of 12.50% and 25.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Telesis Bio to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 8
GlobeNewsWire
02 ноя 2022 г. в 16:19
SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2022 financial results on Tuesday, November 8, 2022, after the market closes. In conjunction with the release, management will host a conference call the same day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights.
Codex DNA (DNAY) Could Find Support Soon, Here's Why You Should Buy the Stock Now
Zacks Investment Research
26 авг 2022 г. в 11:18
After losing some value lately, a hammer chart pattern has been formed for Codex DNA (DNAY), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Codex DNA, Inc. (DNAY) CEO Todd Nelson on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
14 авг 2022 г. в 08:26
Codex DNA, Inc. (NASDAQ:DNAY ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Todd Nelson - Chief Executive Officer Brent Hunter - VP of Finance Conference Call Participants Brandon Couillard - Jefferies Operator Good day, and thank you for standing by. Welcome to the Q2 2022 Codex DNA, Incorporated Earnings Conference Call.